Anti-TNFSF13B therapeutic antibody (Pre-made Belimumab biosimilar,Whole mAb) is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic).

Belimumab, sold under the brand name Benlysta, is a human monoclonal antibody that inhibits B-cell activating factor (BAFF), also known as B-lymphocyte stimulator (BLyS). It is approved in the United States, Canada, and the European Union to treat systemic lupus erythematosus (SLE).

Order informatioin

Delivery impact due to the Coronavirus Outbreak

With the COVID-19 outbreak in the world, many flights have been cancelled. In order for the customer to receive the goods properly, we use the FedEx Customized Freight (FCF) of Fedex which demands a higher fee. If the delivery fee is more expensive in your area, we will contact you by mail.

Catalog No.	Package	Price(In USD)	Qty (Quantity)	Sum(In USD)
GMP-Bios-ab-056-1mg	1mg	3090
GMP-Bios-ab-056-10mg	10mg	21890
GMP-Bios-ab-056-100mg	100mg	148000
GMP-Bios-ab-056-xmg	≥100mg	Inquiry
			Shipping Cost:	760.00
			Total:

Description

Products Name (INN Index)	Anti-TNFSF13B therapeutic antibody (Pre-made Belimumab biosimilar,Whole mAb)
INN Name	Belimumab
Target	TNFSF13B
Format	Whole mAb
Derivation	Human
Species Reactivity	Human
CH1 Isotype	IgG1
VD LC	Lambda
Highest_Clin_Trial (Jan '20)	Approved
Est. Status	Active
100% SI Structure	5y9k:HL/5y9j:HL/6fxn:OP:QR:MN:FG:HI:DE
99% SI Structure	None
95-98% SI Structure	6erx:HI:DE:QR:MN:FG:OP
Year Proposed	2003
Year Recommended	2004
Companies	Assistance Publique Hopitaux de Paris;Cancer Trials Australia;GlaxoSmithKline;Hospital for Special Surgery;Human Genome Sciences;North Shore-Long Island Jewish Health System;University of Alabama at Birmingham;University of Pennsylvania;University of Wisconsin-Madison;Washington University School of Medicine;Cambridge Antibody Technology
Conditions Approved	Systemic lupus erythematosus;Lupus nephritis
Conditions Active	Anti-neutrophil cytoplasmic antibody-associated vasculitis;Myositis;Emphysema;Membranous glomerulonephritis;Myasthenia gravis;Renal transplant rejection;Systemic scleroderma;Graft-versus-host disease
Conditions Discontinued	Waldenstrom's macroglobulinaemia;Rheumatoid arthritis;Sjogren's syndrome
Development Tech	CAT Phage Display